Akebia Therapeutics

The company's lead product candidate is Vadadustat, a hypoxia inducible factor (HIF) stabilizer that inhibits the prolyl hydrolase (PH) enzyme. It is in Phase 3 of clinical development for patients with renal anemia. Vadadustat is designed to mimic the body's adaptive response to hypoxia, such as that experienced at moderate altitude. The drug is currently an investigational drug and has not yet been approved by the US FDA or any other regulatory authority.

Akebia is developing other HIF-based portfolio of product candidates that target serious diseases of high unmet need. This includes those developed internally as well as in-licensed products.

In December 2018, Akebia merged with Keryx Biopharmaceuticals under the former company's name.

Akebia Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts. It is focused on the development and commercialization of therapeutics for patients with chronic kidney disease.